Valion Bio appoints Armand Balboni as advisor as Entolimod study advances
Valion Bio said Armand Balboni will advise on scientific strategy, medical countermeasures and government and industry partnerships as Entolimod advances through a therapeutic efficacy study.
Valion Bio, Inc. (NASDAQ:VBIO) has appointed Armand Balboni, JD, MD, PhD, as an advisor on scientific strategy and medical countermeasure development. The company said his work will centre on Entolimod, its lead medical countermeasure candidate, as a therapeutic efficacy study examines outcomes following radiation exposure.
Valion Bio said Dr. Balboni will help shape its scientific approach to Entolimod and support efforts to develop government and industry partnerships. The company described the appointment as bringing together experience in drug development, regulatory affairs, military medicine and strategic collaboration.
Entolimod is being studied for survival and gastrointestinal recovery after radiation exposure. Valion Bio did not provide a date for the study's data readout in the announcement.
Dr. Balboni previously served as chief executive officer of Appili Therapeutics Inc., where he was responsible for corporate strategy, clinical development and regulatory work. His tenure included oversight of a 1,500-patient Phase 3 trial assessing an antiviral treatment for COVID-19.
He also spent 24 years in the U.S. military and held senior roles within the U.S. Army. His responsibilities included work involving FDA-regulated trials, regulatory submissions, emergency use authorisations and the assessment and procurement of medical technologies for military requirements.
Dr. Balboni served as deputy director of the U.S. Army’s Office of Regulated Activities and completed a Department of Defense fellowship at the FDA. He also worked at the U.S. Army Medical Research Institute of Infectious Diseases, where he directed technology transfer and collaborations involving universities, government agencies and biotechnology and pharmaceutical companies.
Valion Bio is developing Entolimod as a potential medical countermeasure for Acute Radiation Syndrome, radiation-induced neutropenia and other indications. The company holds an exclusive, worldwide licence from Statera Biopharma covering development and commercialisation of the candidate for those uses.
The company said Entolimod has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration. Its development is being conducted under the FDA’s Animal Rule, which can permit approval based on animal efficacy studies when human trials are not ethical or feasible.
Valion Bio describes Entolimod as a Toll-like Receptor 5 agonist intended to activate signalling associated with cellular protection, tissue recovery and immune response.
Valion Bio is also advancing Entolasta, a next-generation TLR5 agonist designed for potential broader applications, including oncology supportive care. The company’s pipeline includes potential programmes in neutropenia and immune dysfunction.
Its wholly owned subsidiary, Velocity Bioworks, operates as a biologics contract development and manufacturing organisation with mammalian and microbial capabilities. Valion Bio said the subsidiary is focused on manufacturing control, costs, development timelines and domestic supply-chain security.
Valion Bio cautioned that statements concerning trial timing and results, Entolimod’s regulatory progress, government interactions, Entolasta, additional capital and continued listing on the Nasdaq Capital Market are subject to substantial risks and uncertainties. The company said actual results could differ from its forward-looking statements and referred readers to its filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 30, 2026.
Valion Bio announced that Armand Balboni, JD, MD, PhD, had become an Advisor on its scientific strategy and medical countermeasure development efforts. His focus will include advancing Entolimod and pursuing government and strategic partnerships.
Dr. Balboni will advise Valion Bio on scientific strategy, Entolimod development and medical countermeasures. Valion Bio said his mandate is to lead its scientific strategy and pursue government and industry partnerships.
Valion Bio said the advisory role combines scientific, regulatory and military medical expertise as the company prepares for a key development milestone for Entolimod. Entolimod is advancing through a therapeutic efficacy study evaluating survival and gastrointestinal recovery following radiation exposure.
Valion Bio said the therapeutic efficacy study is evaluating survival and gastrointestinal recovery following radiation exposure. The source does not provide a date for the study's data readout.
Valion Bio said Dr. Balboni's experience covers biotechnology, clinical drug development, military medicine, regulatory affairs and strategic partnerships. He previously served as Chief Executive Officer of Appili Therapeutics Inc. and held senior leadership positions across the U.S. Army, including Deputy Director of the Office of Regulated Activities.
Valion Bio Interim Chief Executive Officer Dean Zikria said Dr. Balboni's experience spans drug development, regulatory execution, military medical requirements and procurement, and strategic partnerships. Zikria said the adviser would pursue government and industry partnerships to advance Entolimod towards its next development milestones.
Dr. Balboni said he selected Valion Bio because Entolimod had Fast Track and Orphan Drug designations, fully funded safety and therapeutic efficacy studies, and a clear regulatory pathway under the FDA's Animal Rule. He said he was excited to help the company advance Entolimod.
Valion Bio is a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its stated areas include conditions driven by radiation, disease and immune dysregulation.
Valion Bio is developing Entolimod as a potential medical countermeasure for Acute Radiation Syndrome, radiation-induced neutropenia and other indications. The company holds an exclusive, worldwide licence from Statera Biopharma to develop and commercialise Entolimod for those uses.
Valion Bio said Entolimod has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration. The company is developing it under the FDA's Animal Rule, which can allow approval based on animal efficacy studies when human clinical trials are not ethical or feasible.
Valion Bio is advancing Entolasta, a next-generation TLR5 agonist designed for potential broader therapeutic applications, including oncology supportive care, and its pipeline includes potential programmes in neutropenia and immune dysfunction. Its wholly owned subsidiary, Velocity Bioworks, is a biologics contract development and manufacturing organisation with mammalian and microbial capabilities.
Valion Bio's common stock is listed on the Nasdaq Capital Market under the ticker symbol NASDAQ:VBIO.
Valion Bio said Entolimod is advancing through a therapeutic efficacy study and that Dr. Balboni will pursue government and strategic partnerships to advance the programme towards its next development milestones. The release does not give a dated readout or other specific next event.
Valion Bio cautioned that statements about trial timing and results, Entolimod's regulatory advancement, government interactions, Entolasta, additional capital and continued Nasdaq Capital Market listing are subject to substantial risks and uncertainties. The company said actual results could differ from those in its forward-looking statements and directed readers to its SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2025.